The Food and Drug Administration on Tuesday announced it approved Retacrit, a biosimilar to Epogen/Procrit, for the treatment of anemia.
According to a press release, the biosimilar can be used in treatment of anemia caused by:
- Chronic kidney disease;
- Chemotherapy; and
- Use of zidovudine in patients with HIV infection.
The FDA says Retacrit can also be used prior to surgery to reduce the risk of red blood cell transfusions.
“It is important for patients to have access to safe, effective and affordable biological products and we are committed to facilitating the development and approval of biosimilar and interchangeable products,” Leah Christl, director of the Therapeutic Biologics and Biosimilars Staff in the FDA’s Center for Drug Evaluation and Research.
Christl said biosimilars have the potential to not only boost competition and possibly lower costs, but also deliver “greater access to treatment options for patients.”
To read the full press release on the FDA’s website, click here.